Related Experiment Videos
DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot
Gil Zalsman1, Amos Frisch, Shaul Lev-Ran
1Adolescent Inpatient Department, Geha Mental Health Center, Rabin Medical Center, Petach Tikva 49100, Israel. zalsman@post.tau.ac.il
Abstract:
This study examined the possible association between the polymorphism in the dopamine receptor DRD4 gene and response to risperidone among 24 Israeli Jewish adolescent inpatients with first-episode schizophrenia. Response was categorically determined by a change of >40% on the Brief Psychiatric Rating Scale (BPRS). No significant association was found between the DRD4 genotype and clinical response, although carriers of <7 repeat alleles demonstrated higher response rate (10/20 vs. 0/4, P=0.11). Studies in larger groups of adolescent schizophrenia patients are warranted to clarify the possible association between DRD4 exon III repeat alleles and the response to risperidone.